These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10146911)

  • 1. Indirect costs in economic studies: confronting the confusion.
    Koopmanschap MA; Rutten FF
    Pharmacoeconomics; 1993 Dec; 4(6):446-54. PubMed ID: 10146911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The friction cost method for measuring indirect costs of disease.
    Koopmanschap MA; Rutten FF; van Ineveld BM; van Roijen L
    J Health Econ; 1995 Jun; 14(2):171-89. PubMed ID: 10154656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.
    Holko P; Kawalec P; Mossakowska M; Pilc A
    PLoS One; 2016; 11(12):e0168586. PubMed ID: 27992531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect costs and incidence of caregivers' short-term absenteeism in Poland, 2006-2016.
    Łyszczarz B
    BMC Public Health; 2019 May; 19(1):598. PubMed ID: 31101035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost of lost productivity in pharmacoeconomics analysis. Part I. A systematic review of the literature].
    Wrona W; Hermanowski T; Golicki D; Jakubczyk M; Macioch T; Goszczyńska K; Wójcik R
    Przegl Epidemiol; 2011; 65(1):147-52. PubMed ID: 21735852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Productivity loss due to overweight and obesity: a systematic review of indirect costs.
    Goettler A; Grosse A; Sonntag D
    BMJ Open; 2017 Oct; 7(10):e014632. PubMed ID: 28982806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The friction-cost method : replacement for nothing and leisure for free?
    Brouwer WB; Koopmanschap MA
    Pharmacoeconomics; 2005; 23(2):105-11. PubMed ID: 15748085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal burden of cluster headache in the United States: a descriptive economic analysis.
    Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
    J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost of lost productivity in pharmacoeconomics analysis. Part II. Survey in the expert group].
    Wrona W; Hermanowski T; Jakubczyk M; Golicki D; Czech M; Niewada M; Kolasa K
    Przegl Epidemiol; 2011; 65(1):153-7. PubMed ID: 21735853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.
    Brouwer WB; Koopmanschap MA; Rutten FF
    Health Econ; 1997; 6(3):253-9. PubMed ID: 9226143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the association of smoking with work productivity and associated costs in Japan.
    Suwa K; Flores NM; Yoshikawa R; Goto R; Vietri J; Igarashi A
    J Med Econ; 2017 Sep; 20(9):938-944. PubMed ID: 28685629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective.
    Hubens K; Krol M; Coast J; Drummond MF; Brouwer WBF; Uyl-de Groot CA; Hakkaart-van Roijen L
    Value Health; 2021 Nov; 24(11):1686-1699. PubMed ID: 34711370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a new approach for estimating indirect costs of disease.
    Koopmanschap MA; van Ineveld BM
    Soc Sci Med; 1992 May; 34(9):1005-10. PubMed ID: 1631600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects.
    Krol M; Brouwer WB; Severens JL; Kaper J; Evers SM
    Soc Sci Med; 2012 Dec; 75(11):1981-8. PubMed ID: 22925428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of allergic rhinitis: a critical evaluation of the literature.
    Reed SD; Lee TA; McCrory DC
    Pharmacoeconomics; 2004; 22(6):345-61. PubMed ID: 15099121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect costs of disease; an international comparison.
    van Roijen L; Koopmanschap MA; Rutten FF; van der Maas PJ
    Health Policy; 1995 Jul; 33(1):15-29. PubMed ID: 10172358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland.
    Kawalec PP; Malinowski KP
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):667-73. PubMed ID: 26153642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.